Since the creation of our entity, Aixial has experienced several years of successive growth despite a challenging and competitive environment.

The company aims to become a major player in Research & Development for the pharmaceutical industry but also to be recognized in the integration of Decisional Systems (SAS) market.

To support our growth, we conducted in 2009 reorganizing operations of the company, splitting the various activities in three separate structures:

The pharmaceutical business was split into two structures:

• AIXIAL-Pharma - Biometrics activity

• AIXIAL-CR - Clinical Research Activity

Computer activity has been consolidated into a single structure:

• AIXIAL-BI - business development SAS

The reorganization aims to develop our expertise in each of these distinct areas, bringing more investment and a greater appreciation of our position to stay on a very dynamic pace.

To support our growth, Aixial headquarters have been transferred on 1st July 2009 to larger premises to enable our development projects.